Literature DB >> 15851913

Increased cardiovascular disease risk indices in HIV-infected women.

Sara E Dolan1, Colleen Hadigan, Kathleen M Killilea, Meghan P Sullivan, Linda Hemphill, Robert S Lees, David Schoenfeld, Steven Grinspoon.   

Abstract

Little is known regarding cardiovascular disease risk indices in HIV-infected women. This study investigated cardiovascular disease risk indices in 100 consecutively recruited HIV-infected women and 75 healthy female control subjects. Subjects were recruited from hospital- and community-based health care providers. C-reactive protein (CRP), interleukin-6 (IL-6), adiponectin, lipid, and glucose levels were the main outcome measures. CT scan, dual-energy x-ray absorptiometry (DXA), and anthropometry were used to assess body composition. Although similar in age, weight, and racial composition, HIV-infected women demonstrated higher CRP (4.6 +/- 0.7 vs. 2.3 +/- 0.4 mg/L, P = 0.007), IL-6 (2.7 +/- 0.2 vs. 1.8 +/- 0.1 pg/mL, P = 0.02), triglyceride (1.84 +/- 0.21 vs. 0.85 +/- 0.05 mM, P = 0.0002), 2-hour glucose after oral glucose challenge (6.88 +/- 0.22 vs. 5.72 +/- 0.17 mM, P = 0.0003), and fasting insulin (81 +/- 8 vs. 45 +/- 2 pM, P = 0.0002) and lower high-density lipoprotein cholesterol (1.17 +/- 0.03 vs. 1.45 +/- 0.05 mM, P < 0.0001) and adiponectin (5.4 +/- 0.3 vs. 7.6 +/- 0.5 mg/L, P = 0.0001) levels compared with the control population. HIV-infected women had more abdominal visceral fat and less extremity fat by CT and DXA scan and demonstrated a higher waist-to-hip ratio (WHR) than the control population. Within the HIV group, CRP and other indices were significantly related to body composition in stepwise regression models. Among all subjects, WHR, but not HIV status, was significantly related to CRP and other cardiovascular disease risk indices. HIV-infected women demonstrate significantly increased risk factors for cardiovascular disease in association with abnormal fat distribution.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15851913     DOI: 10.1097/01.qai.0000159323.59250.83

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  64 in total

1.  Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Authors:  Takara L Stanley; Julian Falutz; Jean-Claude Mamputu; Graziella Soulban; Diane Potvin; Steven K Grinspoon
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

2.  Association of HIV, hepatitis C virus and liver fibrosis severity with interleukin-6 and C-reactive protein levels.

Authors:  Shailja Shah; Yifei Ma; Rebecca Scherzer; Greg Huhn; Audrey L French; Michael Plankey; Marion G Peters; Carl Grunfeld; Phyllis C Tien
Journal:  AIDS       Date:  2015-07-17       Impact factor: 4.177

Review 3.  Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.

Authors:  Shobhit Jain; Ninad Desai; Amrit Bhangoo
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

4.  Evidence-Based Management of an Individual Living with HIV.

Authors:  Kelly K O'Brien; Stephanie A Nixon
Journal:  Physiother Can       Date:  2010-07-23       Impact factor: 1.037

5.  The human immunodeficiency virus and the cardiometabolic syndrome in the developing world: an African perspective.

Authors:  Eugene Mutimura; Nigel J Crowther; Aimee Stewart; W Todd Cade
Journal:  J Cardiometab Syndr       Date:  2008

6.  Increased aldosterone among HIV-infected women with visceral fat accumulation.

Authors:  Janet Lo; Sara E D Looby; Jeffrey Wei; Gail K Adler; Steven K Grinspoon
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

7.  Coronary Heart Disease (CHD) Risk Factors and Metabolic Syndrome in HIV-Positive Drug Users in Miami.

Authors:  Marianna K Baum; Carlin Rafie; Shenghan Lai; Lihua Xue; Sabrina Sales; J Bryan Page; Ronald Berkman; Linden Karas; Adriana Campa
Journal:  Am J Infect Dis       Date:  2006

8.  Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study.

Authors:  Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

9.  The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.

Authors:  Siddharth H Sheth; Robin J Larson
Journal:  BMC Infect Dis       Date:  2010-06-23       Impact factor: 3.090

10.  Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study.

Authors:  Todd T Brown; Xiaoqiang Xu; Majnu John; Jaya Singh; Lawrence A Kingsley; Frank J Palella; Mallory D Witt; Joseph B Margolick; Adrian S Dobs
Journal:  AIDS Res Ther       Date:  2009-05-13       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.